ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2773

Whole-Body MRI Reveals Characteristic Extracapsular Pattern of Inflammation in Polymyalgia Rheumatica

Sarah Mackie1, Colin T. Pease2, Eiki Fukuba3, Paul Emery4, Richard J. Hodgson4, Jane E. Freeston5 and Dennis McGonagle6, 1NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, 2Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Department of Radiology, Faculty of Medicine, Shimane University, Shimane, Japan, 4NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Magnetic resonance imaging (MRI) and polymyalgia rheumatica

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Polymyalgia rheumatica (PMR) is a disease of widespread musculoskeletal inflammation characterized by pain and stiffness in shoulder and hip girdles. Here we report the first use of whole-body MRI to study the clinical spectrum of PMR in the rheumatology clinic. We hypothesized that PMR is characterized by an extracapsular pattern of inflammation.

Methods

38 participants underwent whole-body MRI: 22 consecutive cases of clinically-diagnosed, active PMR identified by two rheumatologists with a special interest in PMR and followed up for a mean of 21 months; and 16 patients (controls) selected from a larger inflammatory arthritis (RA) cohort. 4 of the PMR patients did not have gadolinium enhancement, due to contra-indications. Anonymised gadolinium-enhanced MRI scans were consensus scored in axial view using semi-quantitative grading, and the features best discriminating PMR from RA were identified. Patients were treated after the MRI with 15mg prednisolone and then asked at follow-up whether they now felt back to normal.

Results

A characteristic pattern suggesting PMR was classified as “PMR pattern” by the blinded scorers; this could be identified both on the gadolinium-enhanced and non-enhanced scans. The features best discriminating PMR from RA were inflammation in the following sites: extending up around the rim of the acetabulum (“peri-acetabular”); around the ischial tuberosity; within the hip joint; around the greater trochanter; and around the symphysis pubis (Figure). Of all the MRIs performed in patients with a clinical diagnosis of PMR, “PMR pattern” was significantly associated with patient-defined glucocorticoid responsiveness (p=0.01).

Conclusion

A characteristic, extracapsular pattern of inflammation in PMR can be identified, and defines a subgroup of the clinical spectrum of PMR with excellent patient-reported glucocorticoid responsiveness. MRI is particularly useful in assessing inflammation of structures around the pelvis.


Disclosure:

S. Mackie,
None;

C. T. Pease,
None;

E. Fukuba,
None;

P. Emery,

AbbVie, Bristol-Myers Squibb (BMS), MSD, Novartis, Pfizer Inc, Roche, and UCB Pharma,

2,

AbbVie, Bristol-Myers Squibb (BMS), MSD, Novartis, Pfizer Inc, Roche, and UCB Pharma,

5;

R. J. Hodgson,
None;

J. E. Freeston,
None;

D. McGonagle,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-body-mri-reveals-characteristic-extracapsular-pattern-of-inflammation-in-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology